Clover Health Investments, Corp. · NASDAQ:CLOV
Clover Health Investments — Investor Presentation (March 2025)
27 slides from Clover Health Investments's investor presentation, March 2025
Slide 1: Investor Presentation
Investor Presentation March 2025
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying oral presentation include forward-looking statements, including, without limitation, statements regarding future events and Clover Health Investments, Corp.’s (“Clover Health,” “we,” “our,” or “us”) expectations regarding Adjusted EBITDA, Adjusted Ne
Slide 3: Our Vision
Our Vision Empower Every Physician with Technology to Identify, Manage & Treat Chronic Diseases Earlier Earlier Diagnosis Earlier Disease Higher Quality Affordable & & Treatment Management Clinical Care Accessible Care 3
Slide 4: A Different Approach to Empowering Accessible & Affordable Healthcare
A Different Approach to Empowering Accessible & Affordable Healthcare Technology-Centric Better Chronic Care Platform Disease Management Better care for chronic diseases. Physician enablement technology, Demonstrated by Clover’s white papers on powered by AI CKD, Diabetes, and Medication Adherence(1
Slide 5: Having Supported Clinical Decision-Making for Thousands of Practitioners
Having Supported Clinical Decision-Making for Thousands of Practitioners Captures & synthesizes Novel clinical insights data from 100+ sources at point-of-care Enhanced care coordination 100+ AI / ML models powering treatment Generating millions of recommendations clinically oriented and personalize
Slide 6: Care Platform: Clover Assistant is the Leader in Clinical AI
Care Platform: Clover Assistant is the Leader in Clinical AI Synthesis of 100+ Insights from >100 Clinical Orientation, Data Sources Proprietary Models Dynamic Actions Millions of clinical Robust IP and patent Surfacing relevant clinical documents, collected & portfolio(1) suggestions at time of rec
Slide 7: Care Platform: Differentiated Home Care at Critical Moments
Care Platform: Differentiated Home Care at Critical Moments Longitudinal, MD-led, primary care in the home for highest acuity population Clover Home Care Cohort has Readmission prevention and Significantly Improved MCR post-acute Care from 2021 to 2024(1) Assessment visits for unknown / emerging ris
Slide 8: Differentiated, Tech-Centric Model Focused on Improving Clinical Care Outcomes via Software
Differentiated, Tech-Centric Model Focused on Improving Clinical Care Outcomes via Software Clover’s Approach Traditional MA Approaches Clinical, physician enablement, InsurTech, centered on back-office, admin Technology AI-Powered technology platforms for claims processing & scheduling Earlier dise
Slide 9: New Revenue Opportunity: Counterpart Health Brings Clover's Care Model to More Plans & Providers
New Revenue Opportunity: Counterpart Health Brings Clover’s Care Model to More Plans & Providers Health outcomes improved via earlier identification, management, & treatment of disease Complementary offering to drive growth & profitability beyond Clover’s core MA markets New SaaS & Tech-Enabled Serv
Slide 10: Our Opportunity
Our Opportunity
Slide 11: Clover's Next Phase: Growth
Clover’s Next Phase: Growth 2024 Results 2025 Guidance(1) 2026 Tailwinds Strong Performance Balancing Growth & Profitability Poised for Accelerated Profitability +27% AEP growth MA membership +30% YoY(2) Positioned for strong membership growth $1.37B Total Revenue, +9% YoY Insurance Revenue $1.8B -
Slide 12: Positioned to Succeed
Positioned to Succeed Average Medicare Advantage Membership(1) Average MCR Differential by Cohort Year(2) +30% Robust new member growth via MA switchers & core market focus, coupled with compelling cohort management, establishes foundation for long-term Medicare Advantage success (1) Average Medicar
Slide 13: Our Technology-Driven Approach is Working
Our Technology-Driven Approach is Working Grow Membership & Clover Assistant Usage 1 Reinvest in Deliver Better AI Driven Member Benefits 5 2 Clinical Recommendations Reduce the Improve Health Outcomes 4 3 Total Cost of Care & Quality of Life 13
Slide 14: Looking Ahead
Looking Ahead
Slide 15: Our Focus for 2025
Our Focus for 2025 Membership & Revenue Growth: Take advantage of MA market opportunity due to competitor pullback Balance Profitability & Reinvestments: Maintain strong Adjusted EBITDA(1) profitability, with strategic investments in growth, Clover Assistant technology & reach, and Home Care service
Slide 16: Appendix
Appendix
Slide 17: Well-Rounded Management Team of Technology Experts & Seasoned Managed Care Professionals
Well-Rounded Management Team of Technology Experts & Seasoned Managed Care Professionals Vivek Garipalli Andrew Toy Executive Chairman ______________________________________________________________________________________________ Chief Executive Officer ______________________________________________
Slide 18: Quality: Clover Leads the Nation on HEDIS Measures
Quality: Clover Leads the Nation on HEDIS Measures(1) Top 10 HEDIS-Scoring Plans Life-Weighted Average HEDIS Raw Score(3) HEDIS Weighted Rank Plan(2) Contract Plan Type Raw Score Clover Health rated 4.94 / 5 Stars on HEDIS Measures for Star Rating Year 2025 (1) (1) Clover Health’s Medicare Advantage
Slide 19: Earlier Diagnosis Leads to Earlier Treatment: Kidney Function
Earlier Diagnosis Leads to Earlier Treatment CKD is diagnosed earlier and disease trajectory improves in patients seen by providers using Clover Assistant(1) Example: Chronic Kidney Disease Kidney Function (GFR) Diagnosed CKD Stage 3 CA Patients Diagnosed CKD Stage 3 ~1.5 years Non-CA Patients Time
Slide 20: Earlier Diagnosis Leads to Earlier Treatment: Diabetes Medication Fills
Earlier Diagnosis Leads to Earlier Treatment Patients started on oral diabetic medications Members Newly Diagnosed with Diabetes (1) after Clover Assistant Example: Diabetes raised potential diabetes diagnosis for physician consideration(2) Diabetes Medication Fills Days Since Clover Assistant Visit
Slide 21: Earlier Diabetes Treatment Leads to Better Outcomes
Earlier Diabetes Treatment Leads to: Blood Sugar Indicator Oral Meds Started Non-CA Patients (HbA1c) Better Management of Blood Sugar(1) Oral Meds Started CA Patients Time (Years) Percentage Taking Non-CA Patients Insulin Lower Use of Insulin(1) CA Patients Days Since Oral Meds Started Hypoglycemia
Slide 22: Clover Assistant Correlated with Improved Medication Adherence
Clover Assistant Correlated with Improved Medication Medication fills increased by ~5% on the day of the Clover Assistant visit and remained ~3% higher 90 days post-visit among patients previously non-adherent to Adherence their medications for diabetes, high blood pressure, and high cholesterol(1)
Slide 23: Non-GAAP Financial Measures
Non-GAAP Financial Measures CLOVER HEALTH INVESTMENTS, CORP. RECONCILIATION OF NON-GAAP FINANCIAL MEASURES ADJUSTED SG&A (NON-GAAP) RECONCILIATION (in thousands)(1) (unaudited) (1) The table above includes non-GAAP measures. Non-GAAP financial measures are supplemental and should not be considered a
Slide 24: Non-GAAP Financial Measures (continued)
Non-GAAP Financial Measures (continued) CLOVER HEALTH INVESTMENTS, CORP. RECONCILIATION OF NON-GAAP FINANCIAL MEASURES ADJUSTED EBITDA (NON-GAAP) RECONCILIATION (in thousands)(1) (unaudited) (1) The table above includes non-GAAP measures. Non-GAAP financial measures are supplemental and should not b
Slide 25: Non-GAAP Financial Measures (continued)
Non-GAAP Financial Measures (continued) CLOVER HEALTH INVESTMENTS, CORP. RECONCILIATION OF NON-GAAP FINANCIAL MEASURES ADJUSTED NET INCOME (LOSS) FROM CONTINUING OPERATIONS (NON-GAAP) RECONCILIATION (in thousands)(1) (unaudited) (1) The table above includes non-GAAP measures. Non-GAAP financial meas
Slide 26: Non-GAAP Financial Measures (continued)
Non-GAAP Financial Measures (continued) CLOVER HEALTH INVESTMENTS, CORP. RECONCILIATION OF NON-GAAP FINANCIAL MEASURES INSURANCE BENEFITS EXPENSE RATIO (NON-GAAP) RECONCILIATION (in thousands)(1) (unaudited) (1) The table above includes non-GAAP measures. Non-GAAP financial measures are supplemental
Slide 27: About Non-GAAP Financial Measures
About Non-GAAP Financial Measures We use non-GAAP measures in this presentation, including Adjusted EBITDA, Adjusted Net income (loss) from continuing operations, Adjusted SG&A, and Insurance BER. These non-GAAP financial measures are provided to enhance the reader’s understanding of Clover Health’s
Clover Health Investments — Investor Presentation (March 2025) on 6ix